• ExpreS2ion highlighted maturing Phase I data for ES2B-C001 in 2026, with results already reviewed in August by an independent safety board.
• Most evaluable patients generated an immune response against the HER2 target, with no dose-limiting toxicities reported across tested dose levels.
• The safety board recommended expanding the highest-dose cohort, supporting plans to strengthen the dataset for partnering discussions.
• A primary Phase I readout is targeted for end-2026, with Phase II initiation now aimed for the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ExpreS2ion Biotech Holding AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.